HCR 576 Adverse Events & Post-Marketing Surveillance in Food Products
HCR 576 Adverse Events & Post-Marketing Surveillance in Food Products
If I were working in the Human Resources department of a food company and saw a YouTube video of a consumer reporting severe side effects from one of our combination food products, later ending in their death, I would have to respond immediately. It would be my responsibility to act quickly and with accountability to protect consumers and the company’s integrity. According to the FDA, safeguarding subjects and consumers extends beyond regulatory measures; it entails evaluating safety issues and even withdrawing products whenever necessary (Murphy & Mathieu, 1987). The first steps I would take would be to record the video as a form of documentation, notify the company leadership, and forward the case to our food safety and regulatory affairs department. Similar to the way drug sponsors are required to cooperate with the FDA and conduct reviews of development and safety plans, food companies should also not overlook consumer-reported risks during the post-marketing phase.
The second step would be to report the incident to the Center for Food Safety and Applied Nutrition (CFSAN) of the FDA. Chapter 6 notes the ability of the FDA to pause or terminate trials when the safety of the subjects is at risk (Murphy & Mathieu, 1987). Although food products are not equal to drugs, the principle of safeguarding the population is the same. The FDA states that every spontaneously reported event is treated as potentially related to the product and must be carefully assessed (Murphy & Mathieu, 1987). Internally, the company would have to probe into the probable source of the adverse event, be it contamination, mislabeling, or ingredient-related reaction. The HR contribution to the process is to organize interdepartmental communication, assist employees through regulatory investigations, and strengthen compliance training. Just as informed consent in drug development requires that participants fully understand the risks before agreeing to take part, food labels must also provide clear information about potential risks. This ensures consumers are well-informed and protected before using the product.
The 2015 Blue Bell Creameries listeria outbreak that caused illnesses and deaths serves as a reminder that food companies should treat post-marketing surveillance with the same seriousness as drug oversight. The FDA emphasizes that if an employee or sponsor recognizes a potential adverse event, they should document and report it, even if the information is received informally, such as in a consumer video (Gliklich et al., 2014). Reporting requirements can be triggered by a minimal dataset including patient, reporter, product exposure, and event (Murphy & Mathieu, 1987). This indicates that a single online complainant can influence regulatory decisions. Besides reporting, businesses are encouraged to investigate potential causes, monitor, and classify events to identify safety signals and improve compliance training. Open communication with regulators, prompt corrective actions, and proactive safety measures are not only regulatory requirements but also vital practices to maintain consumer trust and protect public health.
References
Gliklich, R. E., Dreyer, N. A., & Leavy, M. B. (2014). Adverse event detection, processing, and reporting. In Registries for Evaluating Patient Outcomes: A User’s Guide [Internet]. 3rd edition. Agency for Healthcare Research and Quality (US).
Murphy, W. J., & Mathieu, M. P. (1987). New drug development: a regulatory overview.
CLICK HERE TO ORDER A PLAGIARISM-FREE PAPER
HCR 576 Adverse Events & Post-Marketing Surveillance in Food Products
